N-[(Z)-2-iminoethylideneamino]-2,3-dimethylaniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(Z)-2-iminoethylideneamino]-2,3-dimethylaniline
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.23
• InChiKey: AILDCSSFCKWGAH-NZIGFDOLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  48.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMIDE D'AZÉTIDINE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'ORÉXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014141065A1

  公开（公告）日：2014-09-18

  The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的吡嗪酰胺衍生物衍生物，其中环A1、A2和A3如描述中所述，其药学上可接受的盐，其制备方法，含有一种或多种式(I)化合物的药物组合物，以及它们作为药物的用途，特别是它们作为促进睡眠的药物。
• Benzimidazole-proline derivatives
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US11040966B2

  公开（公告）日：2021-06-22

  The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.

  本发明涉及式 (II) 的化合物 其中 Ar1、R1、R2、R3、R4a、R4b 和 (R5)n 如描述中所述，涉及它们的制备、其药学上可接受的盐及其作为药物的用途、含有一种或多种式 (II) 化合物的药物组合物，特别是它们作为奥曲肽受体拮抗剂的用途。
• BENZIMIDAZOLE-PROLINE DERIVATIVES
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US20190263797A1

  公开（公告）日：2019-08-29

  The present invention relates to compounds of the formula (II) wherein Ar 1 , R 1 , R 2 , R 3 , R 4a , R 4b and (R 5 ) n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.